US to put up US$2.1 billion for Sanofi, GSK coronavirus vaccine

GSK says its vaccine candidate in development has the potential to play a significant role in overcoming the Covid-19 pandemic. – EPA pic, July 31, 2020.

PHARMA giants Sanofi and GSK will receive up to US$2.1 billion (RM8.9 billion) from the US government for the development of a Covid-19 vaccine, the companies said today, as the world reels from the coronavirus epidemic.

The United States has identified a vaccine candidate under development by Sanofi and GSK for its “Operation Warp Speed,” which aims to rapidly secure millions of doses.

Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!

Subscribe Now!

Sign up or sign in here to comment.